Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02660242 · ClinicalTrials.gov registry record · Phase 2
The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes
A Phase 2 study, sponsored by Jaeb Center for Health Research.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT02660242: Completed Phase 2 study, sponsored by Jaeb Center for Health Research.
NCT02660242 is a Phase 2 study that has completed, run by Jaeb Center for Health Research. The registered enrollment target is 16 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02660242, a Phase 2 study, has completed, sponsored by Jaeb Center for Health Research.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.
Primary Outcome
Comparison of glycemic response (from blood glucose) during exercise and early recovery between each exercise strategy.
Interventions
- DRUG G-Pen Mini™ (glucagon injection)
- OTHER Glucose Tabs
- OTHER Basal Insulin Reduction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 2 |
What the finished NCT02660242 record still lists
NCT02660242 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 3 interventions - of which G-Pen Mini™ (glucagon injection) is the first listed.
NCT02660242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02660242 about?
NCT02660242 is a clinical study titled "The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes". This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.
What is the current status of trial NCT02660242?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2016-01. Estimated completion is 2017-02-15.
What interventions are being tested in trial NCT02660242?
The interventions under investigation include: G-Pen Mini™ (glucagon injection) (DRUG), Glucose Tabs (OTHER), Basal Insulin Reduction (OTHER).
Who is sponsoring clinical trial NCT02660242?
This trial is sponsored by Jaeb Center for Health Research, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02660242's enrollment target sits among peer trials
16 1908th of 2000 higher than 82 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia